

The Department of Health Sciences




SWHSI-2 Trial



Baseline Investigator Case Report Form

FOR STUDY INVESTIGATOR COMPLETION



This project is funded by the National Institute for Health Research Health Technology Assessment Programme (Project number 17/42/94)

Section A – Patient Eligibility and Consent Check

Please complete the checklist below to confirm patient eligibility and consent form completion before proceeding to complete this case report form (CRF).

Note: Informed consent must be obtained prior to any trial procedures being undertaken, including completion of any section of this form.

1.	Have all the inclusion criteria been met?	Yes	No
2.	Are any of the exclusion criteria present?	Yes	No
3.	Has the patient provided written informed consent?	Yes	No

If the patient is eligible and consent has been provided, please read the instructions for completing this CRF:

This CRF may be completed by the principal investigator or a delegated member of staff listed on the SWHSI-2 Trial Delegation Log.

Please refer to the associated SWHSI-2 Trial Specific Procedure for full details of how to complete this CRF.

Please complete all sections of this questionnaire using the spaces provided, and sign off when complete.

Please do not include any patient identifiable information when completing this CRF. When complete, please remove the staple and take a photocopy of the completed CRF for your site records. **Please do not re-staple the original.** Place the unstapled original in a "SWHSI-2 Trial business reply envelope" and send via post to York Trials Unit.

Please proceed to Section B

_	Participant ID:			
<u>Sec</u>	tion B – Patient de	mographics		
1.	Date of Birth	day mon	th year	
2.	Gender	Male	Female	
3.	Ethnicity (please	cross one box only)	
		White	Mixed race	Asian or Asian British
		Black or Blac	ck British	Chinese
		Other ethnic	ity, please specify:	
4.	Smoking status			
	Tobacco	Never	Current	Previous
	E-cigarette	Never	Current	Previous
5.	Alcohol intake:	Yes	No	
	If 'Yes' Average U	nits per week:	units	

Please proceed to Section C

Participant ID:
Section C – Comorbidities
Does the patient currently have any of the following co-morbidities?
If 'Yes', please complete Questions 1 to 6. If 'No', please proceed to Section D.
1. Cardiovascular disease: Yes No If 'Yes' please specify:
Hypertension Myocardial Infarction Angina Heart Failure Other, please specify:
2. Peripheral Vascular Disease: Yes No If 'Yes' please specify: Asymptomatic Claudication Rest Pain Tissue Loss Aneurysm Vasculitis Other, please specify:
3. Diabetes: Yes No If 'Yes' is this controlled by: Insulin Tablet
4. Respiratory conditions: Yes No
5. Neurological conditions: Yes No If 'Yes' please specify: Parkinson's Disease Multiple Sclerosis Epilepsy Spinal injury Other, please specify: Other, please specify: Spinal injury Spinal injury
6. Stroke: Yes No
Please proceed to Section D

Participant ID:		

Section D – Concomitant Medications

Is the patient currently receiving any of the following medications?

| No

Yes

If 'Yes', provide a response for all listed below. If 'No', please proceed to Section E.

Cytotoxic	Yes	No
NSAID	Yes	No
Anti-coagulant	Yes	No
Antiplatelet	Yes	No
Corticosteroid	Yes	No
Immunosuppressant	Yes	No
Vasodilator	Yes	No
Analgesia	Yes	No
If 'Yes', please indicate the type and reason	:	
IV Oral Other:		
Related to SWHSI Other reason	:	
Antibiotic	Yes	No
If 'Yes', please indicate the type and reason		
IV Oral Other:		
Related to SWHSI Other reason	:	

Please proceed to Section E

Section E – Body Mass Index Measurements

Please record the patients:					
Height:	ст	Weight:			Kgs
Please proceed to Sec	ction F				

	Participant ID:
<u>3ec</u> 1.	ction F – Surgery Details Please record the type of surgery that led to this SWHSI: Vascular Colorectal Other (please specify):
2.	Please record the date of the surgery that led to the SWHSI:
3.	Was the surgery: Elective Emergency
4.	Please record the name of the surgery: Laparotomy with bowel resections Laparotomy without bowel resections Excision of pilonidal sinus Hernia repair Minor lower limb amputation Major lower limb amputation Cholecystectomy Hysterectomy Caesarean Section Excisions of skin lesions Surgical debridement of necrotic tissue Incision and drainage of abscess (including related to diabetic foot) Other (please specify):
5.	The contamination level of surgery was:
	Clean (i.e. uninfected wound with no inflammation, and where respiratory, alimentary, genital or uninary tracts are not entered)

	Clean (i.e. uninfected wound with no inflammation, and where ${\sf V}$	nere respiratory, alimentary, ge	enital or urinary tracts are not entered)
	Clean Contaminated (i.e. wound in which respirat conditions and without contamination) Contaminated (i.e. open, fresh or accidental wounds intestinal tract, or where acute non-purulent inflammation is p	, operations where a major bre	
	Dirty (i.e. wound with devitalised tissue, clinical infection or	perforated viscera)	
Did	the surgery involve a surgical implant?	Yes	No

If 'Yes', please provide details: Mesh Prosthesis

Please proceed to Section G

6.

Stent

_	Participant ID:
	tion G – SWHSI Assessment
1.	How many SWHSI does this patient have? 1 2 3 4 5 6+ If the patient has more than one SWHSI, the largest wound will be defined as the reference SWHSI.
2.	Does this patient have a previous history of SWHSI?
3.	The SWHSI arose because (please select all that apply):
	The wound edges could not be approximated
	Of presence of infection/contamination
	Planned to heal by secondary intention for other reasons, please specify:
	Wound dehisced along its entire length. If 'Yes', please provide the date this occurred:
	Wound dehisced along part of its length. If 'Yes', please provide the date this occurred:
	day month year
4.	In your clinical opinion is the SWHSI currently infected?
	If 'Yes', please indicate which features are present. If 'No', please proceed to Question 5.
	Abscess or other evidence of infection (found during re-operation, by radiology or histopath examination)
	Aspirated fluid swab yields organisms and pus cells are present
	Antibiotics prescribed for infection
	Incision spontaneously dehisces or was opened by a surgeon
	Clinician diagnosis
	Purulent drainage
	Fever
	Heat
	Localised swelling
	Localised pain and tenderness
	Redness

Participant ID:			

5. Please record if the wound has any of the following features:

		g reatareer		
Odour	Yes	No		
Slough	Yes	No		
Necrosis	Yes	No		
Granulation Tissue	Yes	No		
Exudate	Yes	No		
If 'Yes', please	indicate if this is:	Low	Medium	High
Other (please specify):	Yes	No		

6. Please grade the SWHSI in terms of tissue involvement: (please select all that apply)

	Full thickness skin loss
	Subcutaneous tissue exposed
	Underlying muscle exposed
	Underlying tendons exposed
	Underlying bone exposed
	Underlying organs exposed
	Tissue involvement unclear due to undermining or devitalised tissue
	Other (please specify):
7.	Please record the wound size: Wound Length: . <t< th=""></t<>
8.	If the patient's wound is located on their foot, please indicate the patients status relating to the following features: Pedal blood flow:
	Neuropathy: Protective sensation intact Protective sensation reduced Protective sensation absent Protective sensation absent

Please proceed to Section H

_					
	Participant ID:				
<u>Sec</u>	tion H – SWHSI Treatments				
1.	Where is the patient currently receiving treatment for their SWHSI?				
	Hospital Outpatient Department	Hospital Ward			
	Community Hospital	Intermediate Care Facility			
	Podiatry Clinic	GP Practice			
	Own Home	Another's Home			
	Nursing Home	Community Clinic			
	Other (please specify):				
2.	Who is primarily responsible for the patient's	care? (please select one option only)			
		neral Practitioner Ward Nurse			
		actice Nurse			
	Other (please specify):				
3.	Is the patient is currently receiving dressings If 'Yes', please provide details of the dressing				
	Alginate	Basic wound contact			
	Cavity Foam	Foam			
	Gauze Ribbon	Hydrocolloid			
	Hydrogel	Hydrofoam/Spun Hydrocolloid			
	Honey	lodine Containing			
	PHMB	Protease Modulating matrix			
	Silver containing	Flamazine silver sulfadiazine dressing			
	Urgotol silver sulfadiazine dressing	Soft polymer			
	Superabsorbent	Vapour permeable film or membrane			
	Negative Pressure Wound Therapy*	Note patient should not be randomised if already receiving NPWT or their SWHSI			
	Other (please specify):				
	Other (please specify):				
	Other (please specify):				

Participant ID:			

4. Is the patient receiving any other treatment for their SWHSI (excluding antibiotics and analgesia reported in Section D)?

If 'Yes', please provide details of the treatments used:					
Wound Management Systems	Emollient	Silver Nitrate Stick			
Dietetic Input	Larvae				
Other (please specify):					
Other (please specify):					

Please proceed to Section I

Section I – Checklist and CRF Sign Off

Other (please specify):

1.	All Sections of the Investigator CRF are complete	Yes	No
2.	All Sections of the Participant CRF are complete	Yes	No
3.	Wound measurements have been completed	Yes	No
4.	Wound photograph has been taken	Yes	No
	If 'No', please indicate why a photograph was not obtained:		

Form Completed by:

*Name:		
Signature:		
Assessor ID:		
Date:	day month y	ear

*Must be reflected in the Delegation of Duties Log

Please proceed to Section J

Participant ID:		

Section J – Randomisation

